Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing firstname.lastname@example.org or calling +44 (0)1707 367554.
Future Positive Seven Meeting Report & Congress Highlights Pack
Future Positive Seven (FP7) took place in London on 24th–25th June 2022 and was Co-Chaired by Dr Julie Doughty (Consultant Breast Surgeon, Gartnavel General Hospital, Glasgow) and Dr Judy King (Consultant Medical Oncologist, Royal Free Hospital, London). FP7 featured clinical lectures, case-based discussions and workshops to share the latest advances in breast cancer care, as well as providing meeting delegates with the opportunity to reflect on the impact of the COVID-19 pandemic at a personal- and service-level. FP7 brought members of the UK breast cancer community back together in person, and provided an opportunity to reconnect with peers.
The FP7 highlights report, summarising the presentations and workshops delivered by the expert faculty, will be available on this page soon.
All data included in the report fall within the relevant product licence for Roche products. Information in the report includes non-Roche medicines that are not licensed in the UK, or being used outside of their licensed indications. Should you require further information on a molecule that is not produced by Roche Products Limited, please contact the relevant manufacturer.
This report is intended to be viewed online in your web browser.
Should you require additional information on breast cancer data presented at the meeting, please click here to contact us.
A key objective of FP7 was to ensure that meeting delegates felt up-to-date with the latest breast cancer data highlights from pathology, radiology, surgery, medical oncology and clinical oncology perspectives. FP7 Co-Chairs have personally selected their breast cancer data highlights from international congresses from the past two years – these can be accessed here.